Raising the bar for cancer therapy models
The DOI matches its Crossref record; 12 of the 12 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Certainly, the limitations of preclinical tools such as inadequate cancer-cell-line and mouse models 2 make it difficult for even the best scientists working in optimal conditions to make a discovery that will ultimately have an impact in the clinic.”
From Raise standards for preclinical cancer research (2012) · cites this paper as [2]
In the citing paper
“Many landmark findings in preclinical oncology research are not reproducible, in part because of inadequate cell lines and animal models.”
From Raise standards for preclinical cancer research (2012) · cites this paper as [2]
Citations
Cites
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Can the pharmaceutical industry reduce attrition rates?
Kola, I., & Landis, J. (2004) · Nature Reviews Drug Discovery · doi:10.1038/nrd1470 · Cited by 4,167
Accelerated Metastasis after Short-Term Treatment with a Potent Inhibitor of Tumor Angiogenesis
Ebos, J. M. L., Lee, C. R., Cruz-Munoz, W., Bjarnason, G. A., Christensen, J. G., & Kerbel, R. S. (2009) · Cancer Cell · doi:10.1016/j.ccr.2009.01.021 · Cited by 1,709
Self-citationMaximizing mouse cancer models
Frese, K. K., & Tuveson, D. A. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2192 · Cited by 717
Murine Models to Evaluate Novel and Conventional Therapeutic Strategies for Cancer
Talmadge, J. E., Singh, R. K., Fidler, I. J., & Raz, A. (2007) · The American Journal of Pathology · doi:10.2353/ajpath.2007.060929 · Cited by 468
Nomura, F., Ohnishi, K., & Tanabe, Y. (1989) · Cancer · doi:10.1002/1097-0142(19891015)64:8<1700::aid-cncr2820640824>3.0.co;2-z · Cited by 305
Munoz, R., Man, S., Shaked, Y., Lee, C. R., Wong, J., Francia, G., & Kerbel, R. S. (2006) · Cancer Research · doi:10.1158/0008-5472.can-05-4411 · Cited by 230
Self-citationIntegrating pharmacology and in vivo cancer models in preclinical and clinical drug development
Peterson, J. K., & Houghton, P. J. (2004) · European Journal of Cancer · doi:10.1016/j.ejca.2004.01.003 · Cited by 223
Assessing therapeutic responses in Kras mutant cancers using genetically engineered mouse models
Singh, M., Lima, A., Molina, R., Hamilton, P., Clermont, A. C., Devasthali, V., Thompson, J. D., Cheng, J. H., Bou Reslan, H., Ho, C. C. K., et al. (2010) · Nature Biotechnology · doi:10.1038/nbt.1640 · Cited by 215
Inaba, M., Kobayashi, T., Tashiro, T., Sakurai, Y., Maruo, K., Ohnishi, Y., Ueyama, Y., & Nomura, T. (1989) · Cancer · Cited by 60
Research works printed but not linked: 2
- Kerbel, R.S. Cancer Biol. Ther. 2, 108–113 (2003).
- Inaba, M. et al. Cancer 64, 1577–1582 (1989). · doi:10.1002/1097-0142(19891015)64:8<1577::aid-cncr2820640803>3.0.co;2-i
Cited by
Raise standards for preclinical cancer research
Begley, C. G., & Ellis, L. M. (2012) · Nature · doi:10.1038/483531a · Cited by 2,979
Antiangiogenic therapy: impact on invasion, disease progression, and metastasis
Ebos, J. M. L., & Kerbel, R. S. (2011) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2011.21 · Cited by 685
Self-citationHealth benefits of resveratrol: Evidence from clinical studies
Singh, A. P., Singh, R., Verma, S. S., Rai, V., Kaschula, C. H., Maiti, P., & Gupta, S. C. (2019) · Medicinal Research Reviews · doi:10.1002/med.21565 · Cited by 523
“The discrepancies so far observed between clinical and preclinical studies could be explained by (a) concentration differences of resveratrol used in preclinical models versus those achieved in human studies, or (b) the fact that cell lines and animal models used in the preclinical studies only inadequately recapitula…”
ResultMouse models of advanced spontaneous metastasis for experimental therapeutics
Francia, G., Cruz-Munoz, W., Man, S., Xu, P., & Kerbel, R. S. (2011) · Nature Reviews Cancer · doi:10.1038/nrc3001 · Cited by 374
“Excellent correlation was found when clinically relevant end points were used, such as progression-free survival based on imagin”
MethodSelf-citationChesi, M., Matthews, G. M., Garbitt, V. M., Palmer, S. E., Shortt, J., Lefebure, M., Stewart, A. K., Johnstone, R. W., & Bergsagel, P. L. (2012) · Blood · doi:10.1182/blood-2012-02-412783 · Cited by 214
Metadata
- Authors
- Francia, G., & Kerbel, R. S.
- Affiliations
- Sunnybrook Health Science Centre (CA)
- Corresponding author
- Francia, Giulio
- Kerbel, Robert S
- Venue
- Nature Biotechnology
- Published
- 2010-06
- Volume
- 28
- Issue
- 6
- Pages
- 561-562
- ISSN
- 0733-222X (ISSN-L)
- 1087-0156
- 1546-1696
- OpenAlex
- W2082354253
- Cited by
- 54
- References
- 11
- Citations by year
- 2026: 1 · 2025: 1 · 2024: 1 · 2023: 1 · 2022: 1 · 2021: 1 · 2020: 2 · 2019: 5 · 2018: 3 · 2017: 2 · 2016: 9 · 2015: 3 · 2014: 6 · 2013: 6 · 2012: 6
- FWCI
- 2.85
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Biotechnology (publishedVersion)
- PubMed (publishedVersion)
- scholarworks - UTEP (The University of Texas at El Paso) (submittedVersion)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Cells and Metastasis
- Health Sciences › Veterinary › Small Animals › Animal testing and alternatives
- Health Sciences › Veterinary › Small Animals › Veterinary Oncology Research
- Keywords
- mouse tumor model, preclinical cancer models, cancer therapy, translational oncology
- MeSH terms
- Animals, Disease Models, Animal, Genetic Engineering, Humans, Neoplasms, Randomized Controlled Trials as Topic, Clinical Trials, Phase III as Topic, Xenograft Model Antitumor Assays, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Raising the bar for cancer therapy models. https://app.cochat.ai/papers/10.1038/nbt0610-561
- The paper
- Francia, G., & Kerbel, R. S. (2010). Raising the bar for cancer therapy models. Nature Biotechnology. https://doi.org/10.1038/nbt0610-561
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.